Cancer biomarkers: selecting the right drug for the right patient

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature reviews. Drug discovery

• Publication date

  2012-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrd3651PMID 22322254
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Integrating predictive biomarkers and classifiers into oncology clinical development programs

  2014cited by this paper
• Biomarkers of Barrett's esophagus.

  2014cited by this paper
• Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

  2012cited by this paper
• Adaptive clinical trials in oncology

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease

  2011cited by this paper
• Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Epigenetics in cancer: what's the future?

  2011cited by this paper
• Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

  2011cited by this paper
• Molecular Predictors of Response to Therapy for Breast Cancer

  2011cited by this paper
• Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

  2011cited by this paper
• Taming the dragon: genomic biomarkers to individualize the treatment of cancer

  2011cited by this paper
• Targeting the missing links for cancer therapy

  2011cited by this paper
• Accelerated approval of oncology products: the food and drug administration experience.

  2011cited by this paper
• Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

  2011cited by this paper
• Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

  2011cited by this paper
• The BATTLE trial: personalizing therapy for lung cancer.

  2011cited by this paper
• Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Circulating Tumor Cells as Biomarkers in Prostate Cancer

  2011cited by this paper
• The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.

  2011cited by this paper
• Circulating tumor cells in breast cancer: A tool whose time has come of age

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Cancer genomics: from discovery science to personalized medicine

  2011cited by this paper
• Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application

  2011cited by this paper
• Circulating Tumors Cells as Biomarkers: Progress Toward Biomarker Qualification

  2011cited by this paper
• Integrating predictive biomarkers and classifiers into oncology clinical development programmes

  2011cited by this paper
• Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.

  2011cited by this paper
• The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration

  2011cited by this paper
• Clinical Cancer esearch ing , Diagnosis , Prognosis omparison of PAM 50 Intrinsic Subtyping with unohistochemistry and Clinical Prognostic Factors in oxifen-Treated Estrogen Receptor – Positive R ast Cancer

  2010cited by this paper
• How to improve R&D productivity: the pharmaceutical industry's grand challenge

  2010cited by this paper
• The Cross-Validated Adaptive Signature Design

  2010cited by this paper
• The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

  2010cited by this paper
• Biomarker-adaptive clinical trial designs.

  2010cited by this paper
• Mutational Heterogeneity in Human Cancers : Origin and Consequences

  2010cited by this paper
• Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

  2010cited by this paper
• The role of the microenvironment in mammary gland development and cancer.

  2010cited by this paper
• Randomized clinical trials with biomarkers: design issues.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Is 18F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non–Small Cell Lung Cancer?

  2010cited by this paper
• Comparing breast cancer risk assessment models.

  2010cited by this paper
• Molecular markers for the diagnosis and management of ductal carcinoma in situ.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Mutational heterogeneity in human cancers: origin and consequences.

  2010cited by this paper
• A policy approach to the development of molecular diagnostic tests

  2010cited by this paper
• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development

  2009cited by this paper
• Accumulation of driver and passenger mutations during tumor progression

  2009cited by this paper
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers*

  2009cited by this paper
• The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

  2009cited by this paper
• I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

  2009cited by this paper
• Perspectives on the development of imatinib and the future of cancer research

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Principles of cancer therapy: oncogene and non-oncogene addiction.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Identifying and assessing women at high risk for breast cancer

  2009cited by this paper
• Optimising the design of phase II oncology trials: the importance of randomisation.

  2009cited by this paper
• Noninvasive evaluation of oral lesions using depth‐sensitive optical spectroscopy

  2009cited by this paper
• The future of drug development: advancing clinical trial design

  2009cited by this paper
• Optical imaging for cervical cancer detection: solutions for a continuing global problem

  2008cited by this paper
• Stromal gene signatures in large-B-cell lymphomas.

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• REVIEWTHEME : GENERAL Integration and use of biomarkers in drug development , regulation and clinical practice : a US regulatory perspective

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Randomized Phase III Clinical Trial Designs for Targeted Agents

  2008cited by this paper
• Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design

  2008cited by this paper
• Development and Validation of Biomarker Classifiers for Treatment Selection.

  2008cited by this paper
• Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

  2008cited by this paper
• Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer

  2008cited by this paper
• Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Opinion: The US Food and Drug Administration perspective on cancer biomarker development

  2006cited by this paper
• Converting a breast cancer microarray signature into a high-throughput diagnostic test

  2006cited by this paper
• Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling.

  2006cited by this paper
• Bayesian clinical trials

  2006cited by this paper
• Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

  2006cited by this paper
• Validation of pharmacogenomic biomarker classifiers for treatment selection

  2006cited by this paper
• Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

  2006cited by this paper
• Cancer as an evolutionary and ecological process

  2006cited by this paper
• Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

  2005cited by this paper
• Candidate‐based proteomics in the search for biomarkers of cardiovascular disease

  2005cited by this paper
• New science-based endpoints to accelerate oncology drug development.

  2005cited by this paper
• Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

  2005cited by this paper
• BMC Genomics BioMed Central Methodology article

  2005cited by this paper
• Enrichment designs: efficiency in development of cancer treatments.

  2005cited by this paper
• On the efficiency of targeted clinical trials

  2005cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Reanalysis of Cancer Drugs

  2004cited by this paper
• PTEN function: how normal cells control it and tumour cells lose it.

  2004cited by this paper
• Selectively Advantageous Mutations and Hitchhikers in Neoplasms

  2004cited by this paper
• The biology and clinical relevance of the PTEN tumor suppressor pathway.

  2004cited by this paper
• Human cancer, PTEN and the PI-3 kinase pathway.

  2004cited by this paper

• Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology.

  2026cites this paper
• Development of a sensitive antibody-based label-free electrochemical immunosensors for breast cancer diagnosis

  2025cites this paper
• Microenvironment and Tumor Heterogeneity as Pharmacological Targets in Precision Oncology

  2025cites this paper
• Microfluidic single-cell drug screening: toward personalized precision therapy in chronic myeloid leukemia.

  2025cites this paper
• Improved serum biomarker detection via self-clickable Cu2O nanoparticle-coated Ag slides with oriented and stable antibody presentation on antifouling surfaces.

  2025cites this paper
• Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development

  2025cites this paper
• Lighting Up Dual-Aptamer-Based DNA Logic-Gated Series Lamp Probes with Specific Membrane Proteins for Sensitive and Accurate Cancer Cell Identification.

  2025cites this paper
• Functionalized graphitic carbon nitride as an efficient electro-analytical platform for the label-free electrochemical sensing of interleukin-8 in saliva samples.

  2025cites this paper
• Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

  2024cites this paper
• A Detachable Magnetic Nanodevice for the Efficient Capture and Subtype Identification of Circulating Tumor Cells

  2024cites this paper
• Transcriptomics and epigenetic data integration learning module on Google Cloud

  2024cites this paper
• Benefits from early trial involvement in metastatic colorectal cancer: outcomes from the phase I unit at the Sarah Cannon Research Institute UK

  2024cites this paper
• Biochemical surface functionalization of iron oxide for efficient biomarker detector: A new visions of nano-bio interactions

  2023cites this paper
• REVOLUTIONIZING CANCER TREATMENT: THE ROLE OF NANOTECHNOLOGY IN MODERN ONCOLOGY

  2023cites this paper
• Microfluidics‐based molecular profiling of tumor‐derived exosomes for liquid biopsy

  2023cites this paper
• Laboratory Indications For The Detection Of Adenocarcinoma

  2023cites this paper
• Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience

  2023cites this paper
• Subgroup identification of targeted therapy effects on biomarker for time to event data

  2023cites this paper
• The recent advancements in the early detection of cancer biomarkers by DNAzyme-assisted aptasensors

  2022cites this paper
• Recent computational image workflows advance the spatio-phenotypic analysis of the tumor immune microenviroment

  2022cites this paper
• Antitumor pharmacological research in the era of personalized medicine

  2022influential citation
• Optical Redox Imaging of Treatment Responses to Nampt Inhibition and Combination Therapy in Triple-Negative Breast Cancer Cells

  2021cites this paper
• Live-Cell Imaging of Survivin mRNA by Using a Dual-Color Surface-Cross-Linked Nanoquencher.

  2021cites this paper
• Precision Oncology, Signaling and Anticancer Agents in Cancer Therapeutics.

  2021cites this paper
• The treatment of bipolar disorder in the era of precision psychiatry: Challenges and opportunities

  2021cites this paper
• Application of Artificial Intelligence in the Prevention, Diagnosis and Treatment of Alzheimer’s Disease: New Hope for Dealing with Aging in China

  2021cites this paper
• Simultaneous imaging of cancer biomarkers in live cells based on DNA-engineered exosomes.

  2021cites this paper
• Two-Step Acoustophoresis Separation of Live Tumor Cells from Whole Blood

  2021cites this paper
• Seeking progress in disease modification in Parkinson disease.

  2021cites this paper
• Pharmacological Target Engagement and Validation

  2021cites this paper
• Augmented reality 3D navigation system for percutaneous CT-guided pulmonary ground-glass opacity biopsies: a comparison with the standard CT-guided technique

  2021cites this paper
• Identification of Bladder Cancer at early age in Iraq used by Tumor Marker and Genes Characterization

  2021cites this paper
• Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients

  2021cites this paper
• Analysis on segmentation and biomarker-based approaches for liver cancer detection: A survey

  2020cites this paper
• Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut

  2020cites this paper
• Biostatistics and Bioinformatics in Clinical Trials

  2020cites this paper
• A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

  2020cites this paper
• Developing Novel Anticancer Drugs for Targeted Populations: An Update.

  2020cites this paper
• Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

  2020cites this paper
• Sample size re-estimation in adaptive enrichment design.

  2020cites this paper
• Predicting treatment effects in unipolar depression: A meta-review.

  2020cites this paper
• Identification of a panel of mitotic spindle‐related genes as a signature predicting survival in lung adenocarcinoma

  2020cites this paper
• Therapeutic Targeting of Cancer Cells

  2020cites this paper
• On-chip anticancer drug screening - Recent progress in microfluidic platforms to address challenges in chemotherapy.

  2019cites this paper
• Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants

  2019cites this paper
• Microfluidics as an Enabling Technology for Personalized Cancer Therapy.

  2019cites this paper
• Duodenojejunal Bypass Plus Sleeve Gastrectomy Reduces Infiltration of Macrophages and Secretion of TNF-α in the Visceral White Adipose Tissue of Goto-Kakizaki Rats

  2019cites this paper
• Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

  2019cites this paper
• Comprehensive Knowledge Generation for Radiology and Genetics of Interstitial Lung Diseases (ILDs)

  2019cites this paper
• Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo

  2019influential citation
• Applications of Cytogenetics and Cytogenomics Evaluation techniques in cancer diagnosis: A review

  2019cites this paper
• Cytogenetics and Cytogenomics Evaluation in Cancer

  2019cites this paper
• Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity.

  2019cites this paper
• In silico drug repositioning: from large-scale transcriptome data to therapeutics

  2019cites this paper
• Estrogen conjugated fluorescent silica nanoparticles as optical probes for breast cancer cells imaging.

  2019cites this paper
• Clinical Application of Molecular Features in Therapeutic Selection and Drug Development

  2019cites this paper
• Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design

  2019cites this paper
• Waveguiding and SERS Simplified Raman Spectroscopy on Biological Samples

  2019cites this paper
• Precision medicine in resistant Tuberculosis: Treat the correct patient, at the correct time, with the correct drug.

  2019cites this paper
• Precision health: treating the individual patient with chronic obstructive pulmonary disease

  2019cites this paper
• Predicting drug activity against cancer cells by random forest models based on minimal genomic information and chemical properties

  2019cites this paper
• Introduction to precision medicine in COPD

  2019cites this paper
• Serum MicroRNA‐150 Predicts Prognosis for Early‐Stage Non‐Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1

  2018cites this paper
• Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.

  2018cites this paper
• Cancer Diagnostics and Therapeutics

  2018cites this paper
• Bayesian basket trial design with exchangeability monitoring

  2018cites this paper
• Review: Microfluidics technologies for blood-based cancer liquid biopsies.

  2018cites this paper
• Reducing WBC background in cancer cell separation products by negative acoustic contrast particle immuno-acoustophoresis.

  2018cites this paper
• Estimating mean local posterior predictive benefit for biomarker-guided treatment strategies

  2018cites this paper
• ILDgenDB: integrated genetic knowledge resource for interstitial lung diseases (ILDs)

  2018cites this paper
• Predicting drug effectiveness in Cancer Cell Lines using Machine Learning and Graph Mining

  2018influential citation
• Integrating genomic signatures for treatment selection with Bayesian predictive failure time models

  2018cites this paper
• A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.

  2018cites this paper
• Cancer chemotherapy failure: a synthetic view

  2018cites this paper
• A review of microfluidic approaches for investigating cancer extravasation during metastasis

  2018cites this paper
• Detection of sputum cofilin-1 as indicator of malignancy

  2018cites this paper
• Confidence regions for treatment effects in subgroups in biomarker stratified designs

  2018cites this paper
• Quantifying cancer cell receptors with paired-agent fluorescent imaging: a novel method to account for tissue optical property effects

  2018cites this paper
• Immunotherapy a New Hope for Cancer Treatment: A Review.

  2018cites this paper
• Translational research: Empowering the role of pathologists and cytopathologists

  2018cites this paper
• The molecular limitations of biomarker research in bladder cancer

  2018cites this paper
• Percutaneous low-dose CT-guided lung biopsy with an augmented reality navigation system: validation of the technique on 496 suspected lesions.

  2018cites this paper
• Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy

  2018cites this paper
• Exosomal small RNA sequencing uncovers the microRNA dose markers for power frequency electromagnetic field exposure

  2018cites this paper
• Perspectives for Characterizing Drug Component of Theranostic Products Containing Nanomaterials

  2018cites this paper
• Advances in nanotechnology for cancer biomarkers

  2018cites this paper
• State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia

  2018cites this paper
• Next-generation Metabolomics in the Development of New Antidepressants: Using Albiflorin as an Example.

  2018cites this paper
• Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study

  2018cites this paper
• Intensive care medicine in 2050: clinical trials designs

  2018cites this paper
• Nuclear receptors in cancer — uncovering new and evolving roles through genomic analysis

  2017cites this paper
• Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ

  2017cites this paper
• A common challenge in older adults: Classification, overlap, and therapy of depression and dementia

  2017cites this paper
• Translational Application of Biomarkers

  2017cites this paper
• Multiplex Biomarker Techniques: Methods and Applications

  2017cites this paper
• Integration Of Mutation And Gene Expression Data To Identify Disease Subtypes

  2017cites this paper
• Pancreatic cancer models for translational research

  2017cites this paper
• Precision Oncology: Who, How, What, When, and When Not?

  2017cites this paper
• Anti-IL8/AuNPs-rGO/ITO as an Immunosensing Platform for Noninvasive Electrochemical Detection of Oral Cancer.

  2017cites this paper
• Albumin removal from human serum using surface nanopockets on silica-coated magnetic nanoparticles.

  2017cites this paper